The standard treatment for localized breast cancer is based on conservative surgery (when possible) followed by radiation therapy (RT) delivered to the whole breast. The recommended total RT dose is 45 to 50 Gy delivered in 4.5 to 5 weeks followed by a 10 to 16 Gy boost to the tumor bed for 1 to 1.5 weeks. The rationale for the development of APBI was based on the difficulty for many patients to reach RT centers to receive standard whole breast irradiation (WBI) after conservative surgery. APBI offers decreased overall treatment time and several theoretical advantages over WBI, including a decrease in dose delivered to uninvolved portions of the breast and adjacent organs. If equivalence between the two treatments can be shown, then APBI will be considered as a historic evolution in breast cancer management. In this phase III trial, designed in postmenopausal women \>50 years of age, the objective is to compare the effectiveness and safety of APBI compared with whole breast irradiation. This study is also designed to ensure high quality criteria for surgery, pathology and RT techniques in the 3 arms and will allow to provide data on economics and costs.
Following breast conservative surgery, patients will be stratified according to the following prognostic factors using a minimisation technique: age (\<70 vs ≥70), HER2 status (HER2+ vs HER2-), hormonal receptor status (RH+ vs RH-) and lymph node invasion (pN0 vs pN0i+). Patients will be allocated to receive either standard treatment, hypofractionated treatment or APBI. Radiation therapy should be started between 4 and 12 weeks after the last surgery. Patients treated with standard whole breast irradiation will receive a total dose of 50 Gy in 25 fractions, 2 Gy per day, 5 days a week. The boost of 16 Gy will be delivered in 8 fractions for all patients after completion of the 50 Gy, without interruption. All patients will receive one fraction per day, 5 fractions a week. Patients treated with hypofractionated irradiation will receive a total dose of either 40 Gy (in 15 fractions, 2.66 Gy per day) or 42.5 Gy (in 16 fractions, 2.65 Gy per day) 5 days a week. Patients treated with APBI will receive a total dose of 40 Gy in 10 fractions, delivered twice a day over a time period of 5-7 days. Each daily dose must be separated by 6 hours. Patients will be followed at 3 and 6 month after the last dose of irradiation, at 12 months after the date of last surgery and then on a yearly basis during 10 years.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,006
Whole Breast Irradiation 50 Gy + Boost 16 Gy or Whole breast, either 40 Gy in 15 fractions in 3 weeks or 42.5 Gy in 16 fractions in 3 weeks
Tumor bed 40 Gy in 10 fractions, 2 fractions of 4 Gy per day in 5 to 7 days.
Centre de traitement des Hautes energie - Clinique de l'Europe
Amiens, France
Centre Hospitalier Universitaire
Amiens, France
Institut Bergonié
Bordeaux, France
Centre Hospitalier
Brivé, France
Centre Francois Baclesse
Caen, France
CH Chambery
Chambéry, France
Hopital Henri Mondor
Créteil, France
Centre Leonard de Vinci
Dechy, France
CHU Michallon
Grenoble, France
Hôpital Robert Boulin
Libourne, France
...and 24 more locations
rate of local recurrence
To estimate and compare the rate of local recurrence between the experimental and control arms.
Time frame: 5 years
Ipsilateral breast recurrence-free survival
To evaluate Ipsilateral breast recurrence-free survival
Time frame: 10 years
Nodal regional recurrence-free survival
To evaluate nodal regional recurrence-free survival
Time frame: 10 years
Distant recurrence-free survival
To evaluate distant recurrence-free survival
Time frame: 10 years
Disease-specific survival
To evaluate disease-specific survival
Time frame: 10 years
Overall survival
To evaluate the overall survival
Time frame: 10 years
Toxicities: Measurement of the rate and type of toxicity (acute and late toxic effects)
To evaluate rates and type of acute and late toxicities
Time frame: 10 years
Cosmetic: comparison of the cosmetic result (according to both the physician and the patient)
To evaluate Cosmetic results (Patient and Physician evaluations)
Time frame: 10 years
Quality of Life and Satisfaction
To evaluate the patient quality of life and patient satisfaction
Time frame: 10 years
Medico-economic study
To evaluate the cost of APBI compared with Standard and Hypofractionated irradiation
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.